Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples.
ACE-2 receptor binding inhibition assay
EliA
Neutralizing antibodies
SARS-CoV-2
Journal
Journal of immunological methods
ISSN: 1872-7905
Titre abrégé: J Immunol Methods
Pays: Netherlands
ID NLM: 1305440
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
12
10
2021
revised:
11
03
2022
accepted:
11
03
2022
pubmed:
20
3
2022
medline:
20
4
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
A quantitative, high throughput, fully automated diagnostic method for the detection of neutralizing anti-SARS-CoV-2 antibodies was developed on the Phadia system based on the interaction of SARS-CoV-2 S1 protein and the human ACE-2 receptor. This method was compared to the current state of the art plaque reduction neutralization test (PRNT) and a high correlation between the two methods was observed. Using a large cohort of blood samples from convalescent patients and controls the method displays very high sensitivity and specificity (99,8% and 99.99%, respectively). Neutralizing antibody titers of mRNA-1273 and BNT162b2-vaccinated persons can also be quantified with this method as well. This fully automated method provides the possibility to determine anti-SARS-CoV-2 neutralizing antibody concentrations in just 2 h.
Identifiants
pubmed: 35304119
pii: S0022-1759(22)00045-X
doi: 10.1016/j.jim.2022.113258
pmc: PMC8923036
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113258Informations de copyright
Copyright © 2022 Thermo Fisher Scientific ImmunoDiagnostics Division Freiburg. Published by Elsevier B.V. All rights reserved.
Références
J Immunol Methods. 2021 Jun;493:113043
pubmed: 33773989
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33500361
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Clin Chem Lab Med. 2021 Dec 16;60(3):456-463
pubmed: 34911170
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Int J Infect Dis. 2021 Nov;112:40-44
pubmed: 34481967
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062724
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
J Clin Lab Anal. 2002;16(5):227-32
pubmed: 12357451
Biosaf Health. 2021 Apr;3(2):87-91
pubmed: 33585808
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nat Biomed Eng. 2020 Dec;4(12):1134-1139
pubmed: 33293725
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246